Detalhe da pesquisa
1.
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.
J Psychoactive Drugs
; 46(5): 412-26, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25364994
2.
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Contemp Clin Trials
; 50: 253-64, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27521809
3.
Is exposure to an effective contingency management intervention associated with more positive provider beliefs?
J Subst Abuse Treat
; 42(4): 356-65, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22116009
4.
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.
Addiction
; 107(4): 694-708, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21781202
5.
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.
Drug Alcohol Depend
; 99(1-3): 28-36, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18805656
6.
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
Am J Addict
; 13 Suppl 1: S42-66, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15204675
7.
Response: no more "28 days and you're cured".
Addict Sci Clin Pract
; 4(1): 56-7, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18292711
8.
Response: the claims of public health and public safety.
Sci Pract Perspect
; 2(1): 15-7, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18552717